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BACKGROUND: Chronic liver disease (CLD) is frequently diagnosed at a late stage when prognosis 
is poor. We aimed to determine the patient factors associated with a late CLD diagnosis and its 
subsequent impact on survival in order to support early diagnosis initiatives. 
METHODS: We identified participants of UK biobank (UKB) study who developed first-time 
advanced CLD within 5-years. We identified factors associated with late diagnosis via logistic 
regression, and used survival analysis to measure the association between late CLD diagnosis and 
mortality risk.  
RESULTS: 725 UKB participants developed first-time advanced CLD event within 5-years. 83% of 
cases were diagnosed late. Late diagnosis was associated with aetiology; the odds of late diagnosis 
were twelve times higher for an individual with alcohol-related liver disease (ArLD) versus viral 
hepatitis (aOR:12.01;p<0.001). 
Cumulative mortality 5-years after incident advanced CLD was 43.4% (95%CI:39.6-47.0). Late 
diagnosis was associated with a higher risk of post- advanced CLD mortality for patients with 
NAFLD (aHR:2.18; 95% CI:0.86-5.51; p=0.10), but not for other aetiologies.  
CONCLUSIONS: Late CLD diagnosis varies according to aetiology, and is highest for patients with 
ArLD and non-alcoholic fatty liver disease. The association between late diagnosis and post- 




Chronic liver disease (CLD) is a major global public health problem that causes circa two million 
deaths every year from liver cirrhosis and hepatocellular carcinoma (HCC)1. Much of this is 
increasingly being driven by lifestyle related risk factors such as alcohol consumption and obesity2. 
The issue even more impactful given the poor prognosis from CLD, particularly affecting the working 
age population3,4 therefore giving rise to significant socioeconomic impacts. The true financial costs 
of CLD are unknown but estimates suggests the indirect costs could be four time that of the direct 
costs5.Therefore prevention and good management of CLD offers widespread benefits. 
A key hallmark of CLD is that it is frequently not diagnosed until after severe irreversible liver 
morbidity (advanced CLD) –i.e. liver cirrhosis and/or HCC – emerges. For example, data from the 
Lancet liver disease commission3 reported that of more than 4000 individuals admitted to UK 
hospitals for liver cirrhosis or liver failure between 1996-2012, most (73%) had not been referred to a 
specialist liver clinic prior to that event. Furthermore, a UK population based study found that 
approximately 50% of incident CLD presentations were with decompensated liver disease4, when the 
prognosis is extremely poor6.  
Public health policy in the UK is increasingly focused on prevention and early diagnosis7,8, but as yet 
no formal national guidance has been issued on CLD identification. Late CLD diagnosis is associated 
with a poorer prognosis as patients are unable to access interventions that could have prevented them 
developing advanced liver disease. Equally late diagnosis may further disadvantage patients as for 
example patients are less prepared/primed to make appropriate life style changes after advanced liver 
fibrosis onset versus early diagnosis patients9.  
Little is presently known about the patient factors associated with the timing of CLD diagnosis; only a 
handful of studies have explored this issue, and these have been limited to viral hepatitis10,11. Previous 
studies have only examined late diagnosis for patients with viral hepatitis related CLD, Thus far, the 
factors associated with late diagnosis in a community/primary care population – where most CLD 
cases are alcohol or non-alcoholic fatty liver disease (NAFLD) related12 – are unclear.  
The aim of this study was to investigate these twin issues: i) the factors associated with late CLD 
diagnosis in a community cohort and ii) the impact of late diagnosis on subsequent survival - using 






UK biobank (UKB) is a community cohort study of 502,535 individuals aged 40-69 years in the UK.  
Study recruitment took place between May 2006 and July 2010 from 22 assessment centres covering 
all major areas of the UK. Participants completed a detailed health questionnaire and submitted blood 
samples for biomarker and host genotyping analysis. Follow-up data on major health outcome events 
are provided via record linkage to UK mortality, hospital and cancer registries13.  
Study cohort 
The study cohort included all UKB participants who presented for the first time with advanced CLD 
shortly after their UKB interview (i.e. within 5 years). 
Presentation with advanced CLD was defined as either: a) a first time inpatient hospital admission for 
liver cirrhosis, or b) a first time diagnosis of HCC. Hospital admissions due to liver cirrhosis were 
identified using a validated definition previously described by Ratib et al.14 This cirrhosis definition 
comprises a combination of ICD 10 and OPCS4 codes enumerated in eTable 1. We included all 
admissions meeting this ICD cirrhosis definition, irrespective of whether they were elective/planned 
hospital admissions or emergency hospital admissions. Diagnoses of HCC were identified from 
national cancer registers in England, Wales and Scotland, using the ICD code: C22.0. Participants 
who had presented with advanced CLD prior to their UKB interview were excluded from this study. 
Inferring Late diagnosis 
Progression to advanced CLD occurs slowly and is typically a product of decades of liver disease and 
inflammation15. Participants included in this study must all have had significant CLD at the time of 
their UKB interview therefore, by virtue of the fact that they all presented with advanced CLD within 
a short time (i.e.< 5 years) of this date. 
At their UKB interview, each participant was asked to report all “serious medical conditions” 
diagnosed by a doctor. This question was posed during a face-to-face interview with a trained nurse. 
241 distinct medical conditions were reported by all UKB participants in total. We classified each 
diagnosis according to whether it represented a diagnosis of CLD or not. Full details of this 
classification are shown in Appendix A.  
For the purpose of this analysis, individuals who reported a diagnosis of CLD were considered to have 
had a timely diagnosis of CLD. Vice versa, those who did not were considered to have received a late 
diagnosis of CLD.  
Statistical analysis  
This study is based on two distinct, but complementary, analyses (see Supplementary Figure.1). The 
purpose of analysis #1 was to identify individual-level factors associated with a late CLD diagnosis. 
Conversely, the purpose of analysis #2 was to determine the association between a late CLD diagnosis 
and subsequent. 
 
Analysis#1: Individual-level factors associated with a late CLD diagnosis.  
The following variables were considered in analysis #1 as candidate predictors of late diagnosis: age 
at UKB interview, gender, Townsend deprivation score (as tertiles)16; birth outside of the UK; UK 
country of residence; main liver disease aetiology; platelet count; and stomach/abdominal pain for >3 
months prior to UKB interview. Analogous to previous studies14, liver disease aetiology was 
ascertained through a hierarchical definition of: #a) viral hepatitis, #b) autoimmune liver disease in 
the absence of #a; #c) alcohol-related liver disease (ArLD) in the absence of #a-#b; #d) non-alcoholic 
fatty liver disease (NAFLD) in the absence of #a-#c; and #e) other/unknown in the absence of #a-#d. 
These aetiologies were discerned through a combination of hospital admissions and/or information 
reported during the survey interview (see eTable 2).  
The crude association between each candidate predictors and late diagnosis was assessed using 
univariate logistic regression. Predictors variables with a univariate p-value <0.1 were then included 
in a multivariable logistic regression model to identify independently associated factors. 
Analysis#2: Association between a late CLD diagnosis and survival.  
We used survival analysis to assess the association between late diagnosis and post-advanced CLD 
mortality risk. We started follow-up time at the date of first advanced CLD event and ended it at the 
date of mortality (if at all), or the date the mortality registry was complete to (31 Jan 2018 for England 
and Wales participants; or 30 Nov 2016 for Scottish participants)(Supplementary Figure 1). We 
calculated the association between late CLD diagnosis and time to post-advanced CLD death using 
Cox regression models. We assessed this association according to tiered levels of covariate 
adjustment. These tiers were: a) No adjustment, b) Adjustment for sociodemographic factors (age; 
gender; birth outside UK; country of residence; and Townsend deprivation index), c) Adjustment for 
sociodemographic factors + aetiology, and d) Adjustment for sociodemographic +aetiology + disease 
stage-related variables (presence of ascites; renal dysfunction; infection; bleeding varices and HCC at 
index SLM; platelet count at UKB interview).  
We investigated whether the magnitude of association between late diagnosis and mortality varied 
according to the following factors: aetiology, CLD severity, and follow-up time. This was done by 
adding appropriate interaction terms into the Cox regression model. To note, in this analysis, 
individuals with viral hepatitis, autoimmune hepatitis and other/unknown aetiologies were 
amalgamated into a single aetiology category due to the low number of deaths observed in these 
categories. CLD severity was defined in terms of whether one or more complication event was present 
at the index advanced CLD event. The complications we considered here were HCC, ascites, bleeding 
varices, infection and renal dysfunction. Two mutually exclusive follow-up time periods were 
considered: <1 year after incident advanced CLD, and ≥1 year after incident advanced CLD.   
In addition to those in the first analysis, this second analyses included presence of HCC at the index 
advanced CLD episode, presence of  CLD-related complications at the incident advanced CLD event, 





980 participants (0.2%) developed advanced CLD within five years of UKB recruitment. Of these, 
255 were excluded because an earlier advanced CLD event prior to UKB recruitment was identified.  
Thus, our final sample comprised 725 participants, each of whom developed SLM for the first time 
within 5 years of their UKB interview.  93% of these SLM events were related to hospital admissions 
for liver cirrhosis (see Supplementary Figure.2). 
Characteristics of study cohort 
The mean age at UKB recruitment was 59.8 years (sd:6.8), 489 (67%) were male, and 61 (92%) were 
born in the UK. The most common CLD aetiology was ArLD (n=336, 46%), followed by NAFLD 
(n=194, 27%), viral hepatitis (n=73, 10%) and autoimmune liver disease (n=72, 10%). 51% of this 
cohort were in the most deprived tertile (versus 33% for the total UKB sample).  
The mean time between UKB recruitment and incident SLM was 2.7 years and did not vary according 
to liver disease aetiology (see Supplementary Figure.3). 
Late vs timely diagnosis  
The timely diagnosis group comprised 122 (17%) individuals reported at UKB recruitment that they 
had been diagnosed with a CLD-related condition. The most common condition indicated was “liver 
failure/liver cirrhosis” (see Supplementary Figure.4). The remaining 603 (83%) did not indicate any 
knowledge of their CLD, and thus were assumed to have been diagnosed at a later point, which by 
definition, must have been very close to the time of advanced CLD onset.  
Analysis#1: Individual-level factors associated with a late CLD diagnosis and post-advanced CLD 
mortality.  
 The strongest predictor of late diagnosis was liver disease aetiology (see Table 1 and Figure 1). The 
odds of late diagnosis were twelve times higher for an individual with ArLD versus viral hepatitis 
(aOR: 12.01;95% CI: 6.32-22.83). Similarly, the odds of a late diagnosis were seven times higher for 
an individual with NAFLD versus viral hepatitis (aOR: 7.14;95% CI:3.63-14.02).  
Late diagnosis was also associated with symptoms and biomarkers. A platelet count of <100 was 
associated with 62% lower odds of late diagnosis relative to a platelet count exceeding 150 (aOR: 
0.38; 95% CI: 0.18-0.76). The presence of abdominal pain was associated with reduced odds of late 
diagnosis (aOR: 0.49; 95% CI:0.28-0.86).  
Participants were followed-up for 2927 person years post-advanced CLD. The mean follow-up 
duration per individual was 4.0 years (see Table 2).  342 deaths were observed, of which half had a 
liver-related cause (see Supplementary Figure.5). Cumulative mortality at 5 years post- advanced 
CLD was 27.4% (95% CI: 19.2-35.5) and 46.5% (95% CI: 42.4-50.6) for individuals with timely 
diagnosis and late diagnosis, respectively (see Figure 2).  
Analysis#2: Association between a late CLD diagnosis and survival.  
 Late diagnosis was significantly associated with a higher post- advanced CLD mortality risk in 
univariate analysis (HR:1.47: 95% CI: 1.08-2.00; p=0.013), but the association attenuated after 
adjustment for covariates (see Table 3).   
In subgroup analyses, the association between late CLD diagnosis and post- advanced CLD mortality 
varied according to aetiology. It was greater for patients with NAFLD (aHR: 2.18; 95% CI: 0.86-5.51; 
P=0.100) versus patients with ArLD (aHR: 0.82; 95% CI: 0.48-1.40). The p-value for interaction 
however, at 0.11-0.19, was not statistically significant (see Figure.3).  Conversely, there was no sign 
of effect modification with respect to either follow-up time or CLD severity after adjustment for 













Main findings of this study 
Previous studies have demonstrated that many patients do not receive a diagnosis of CLD until after 
the onset of advanced CLD3,10,11,21. Our current understanding of the determinants of this phenomenon 
remains limited, especially in the context of a community cohort. We have exploited a unique 
opportunity to investigate this issue by studying the data of 725 UKB participants that developed 
advanced CLD for the first time shortly after their recruitment interview.  
What this study adds 
 Foremost, our results confirm that late CLD diagnosis is commonplace, applicable to more than 
three-quarters of patients with advanced CLD.  However, we have also extended previous work by 
showing that the odds of a late diagnosis vary according to clinical factors. In particular, we found 
that late diagnosis was strongly influenced by liver disease aetiology; specifically, the odds of a late 
diagnosis were twelve times (aOR: 12.01; p<0.001) greater for an individual with ArLD versus an 
individual with viral hepatitis. Similarly, the odds of late diagnosis were seven times greater (aOR: 
7.14; P<0.001) for an individual with NAFLD versus viral hepatitis.  
 This “aetiology disparity” could reflect a number of factors, including: i) reluctance of general 
practitioners (GPs) to initiate liver disease investigation for patients with ArLD/NAFLD risk factors 
because of a perception that a diagnosis would be futile (i.e. would not change care plan given a 
perception that specialist therapeutic options are limited)22; or ii) more complex risk stratification 
algorithms for NAFLD and ArLD that GPs are not familiar with and/or have difficulty interpreting22–
24. We also found that the odds of a late diagnosis were reduced for individuals with a low platelet 
count and with abdominal pain. This is presumably because these clinical features trigger further 
investigations, that subsequently reveal evidence of CLD. However, most patients had neither of these 
clinical “red flags”, which emphasises the challenge of identifying high risk of advanced CLD 
patients ex ante. Overall, we confirm the limited and suboptimal performance of existing CLD 
diagnostic pathways in community settings. Future research should endeavour to improve these 
pathways – especially for patients with ArLD and NAFLD.  
A second objective of this study was to explore whether late diagnosis is associated with impaired 
post- advanced CLD survival. This might be the case if, for example, non-late diagnosis patients were 
better primed/prepared than late diagnosis patients to adopt and maintain health behaviour changes 
following onset of advanced CLD. We found that late diagnosis patients did have a considerably 
higher five-year cumulative mortality than timely diagnosed patients (see Figure 2) – however, after 
adjustment for relevant covariates, the survival differences were attenuated and a significant effect did 
not persist (see Table 3). This observation could reflect either limited statistical power or a true null 
effect. Interestingly however, our subgroup analysis suggests that the impact of a late diagnosis may 
vary according to aetiology (see Figure 34). I.e. specifically, a late diagnosis appeared to be much 
more detrimental to post- advanced CLD survival for patients with NAFLD (aHR: 2.18; 95% CI: 
0.86-5.51; P=0.10) versus patients with ArLD (aHR: 0.82; 95% CI: 0.48-1.40). Future research should 
explore this finding in greater detail and – if possible -with a greater sample size. This is important -
firstly, because the burden of NAFLD is expected to increase considerably in the next decade25,26. 
Secondly, because the combination of a high underlying mortality rate plus a high prevalence of late 
diagnosis, means that even a very modest association would translate into an appreciable number of 
life years lost. Thirdly because a better understanding of the harms and disbenefits of a late diagnosis 
(in terms of hard clinical endpoints) will conceivably encourage further investment in CLD detection 
initiatives.  
Limitations of this study 
Late diagnosis is an important issue in Hepatology, but it is understudied, meaning that basic 
questions remain unanswered.  The key strength of this study is that we have been able to address 
some of these questions that have been inadequately explored thus far. Our study does have several 
limitations that require note. The first limitation is that we inferred late diagnosis from self-reported 
data; the accuracy of these self-reported data could have been affected by recall bias, “interview 
fatigue” or under-reporting as a result of stigma. However, although stigma varies according to liver 
disease aetiology, we think this is very unlikely to account for the observed “aetiology disparity” 
because stigma is comparably high for viral hepatitis and ArLD27, and yet we observed diametrically 
opposite levels of CLD diagnosis between these two groups. Furthermore, we also checked self-
reported CLD diagnosis for 598 UKB participants with advanced CLD prior to their UKB interview – 
i.e. a “negative control” group that one would assume would all have received a diagnosis of CLD. 
Reassuringly, self-reported diagnosis was vastly higher in this negative control group across all 
aetiologies (see Supplementary Figure.8), but nevertheless it was still short of 100% (69% overall). 
The shortfall may reflect misclassification of CLD diagnosis status, but potentially suboptimal 
communication of liver disease to patients as well28–30. A second limitation is that the UKB sample are 
not representative of the general UK population; on average, UKB participants are more likely to be 
female, older in age, and to live in less socioeconomically deprived areas than non-participants31. We 
are unclear therefore about how generalizable these findings will be to the rest of the UK, and to 
settings outside the UK. Thirdly, we did not have access to data on specific treatments received 
following first cirrhosis hospitalisation, which may have shed more light on the association between 
late CLD diagnosis and subsequent prognosis. Fourth, UKB participants were recruited in 2006-2010 
(median recruitment date was 2009). Thus the situation we report here regarding late diagnosis may 
have subsequently changed, particularly since the publication of new CLD detection guidelines by 
NICE32,33 and the British Society of Gastroenterology34 from 2016. Finally, when assigning 
individuals to viral hepatitis and autoimmune aetiologies, we did not have direct data on appropriate 
blood test results (e.g. HCV antibodies, and autoantibodies), but had to rely instead on ICD codes 
recorded in hospital episodes (see eTable 1).  
Early diagnosis and risk stratification are regarded as being key to improving the prognosis of patients 
with CLD3,35,36. Health care professionals should ensure that risk factors are identified and followed 
up at all contacts. Training outside of general practice may be needed as frequently people with 
hazardous alcohol risk factors present to emergency health and social care settings37, from which a 
process for referral for liver assessment needs to be supported. Furthermore, patients with NAFLD 
related risk factors (e.g. type 2 diabetes) are known to have frequent community or secondary care 
attendances so there are likely to be ample opportunities for risk assessment. Not only is there 
opportunity to identify patients at an earlier stage, but there is an economic necessity as well, given 
the huge cost managing patients with advanced chronic liver disease38,39.  
In conclusion, late CLD diagnosis is commonplace in a community cohort setting, but varies 
markedly according to aetiology. Our results confirm the need for more action at the general 
population/community level to improve early detection of CLD3,40. This is especially true for ArLD 
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40-54 175 (24.1) 141 (80.6) REF (1.00)
55-59 139 (19.2) 110 (79.1) 0.91 (0.53-1.59)
60-64 212 (29.2) 179 (84.4) 1.31 (0.77-2.22)
65+ 199 (27.5) 173 (86.9) 1.60 (0.92-2.80)
Male 489 (67.5) 417 (85.3) REF (1.00) REF (1.00)
Female 236 (32.6) 186 (78.8) 0.64 (0.43-0.96)* 1.07 (0.64-1.79)
1 (least deprived) 168 (23.2) 140 (83.3) REF (1.00)
2 186 (25.7) 156 (83.9) 1.04 (0.59-1.83)
3 (most deprived) 371 (51.2) 307 (82.8) 0.96 (0.59-1.56)
No 664 (91.6) 556 (83.7) REF (1.00)
Yes 61 (8.4) 47 (77.1) 0.65 (0.35-1.23)
England/Wales 669 (92.3) 557 (83.3) REF (1.00)
Scotland 56 (7.7) 46 (82.1) 0.92 (0.45-1.89)
Viral hepatitis 73 (10.1) 38 (52.1) REF (1.00) REF (1.00)
Autoimmune 72 (9.9) 35 (48.6) 0.87 (0.45-1.67) 0.68 (0.33-1.40)
Alcohol 336 (46.3) 314 (93.5) 13.15 (7.00-24.7)** 12.01 (6.32-22.83)**
NAFLD 194 (26.8) 175 (90.2) 8.48 (4.39-16.41)** 7.14 (3.63-14.02)**
other/unknown 50 (6.9) 41 (82.0) 4.20 (1.78-9.87)* 2.88 (1.15-7.21)*
≥150 (normal) 487 (67.2) 415 (85.2) REF (1.00) REF (1.00)
100-149 138 (19.0) 114 (82.6) 0.82 (0.50-1.37) 0.78 (0.44-1.39)
<100 (low) 59 (8.1) 39 (66.1) 0.34 (0.19-0.61)** 0.38 (0.18-0.76)*
missing 41 (5.7) 35 (85.4) 1.01 (0.41-2.49) 1.48 (0.54-4.03)
No 604 (83.3) 511 (84.6) REF (1.00) REF (1.00)
Yes 121 (16.7) 92 (76.0) 0.58 (0.36-0.93)* 0.56 (0.32-0.97)*
725 (100.0) 603 (83.2) - -
† measured at UKB interview





‡ derived via logistic regression. Variable selection criteria for multivariate analysis was p-value<0.10 in univariate analysis. Variables that did not meet this criteria are marked "NA" in 
multivariate column
Table 1: Cohort description and factors associated with late chronic liver disease diagnosis.






















Total persons 603 122 725
total person years follow-up 2333 594 2927
Average years of follow up, per person (mean) 3.9 4.9 4.0
Average years of follow up, per person (median 4.1 5.5 4.3
Number of all-cause deaths 294 48 342
crude all cause mortality rate, per 100 PYs (95% CI) 12.6 (11.2-14.1) 8.1 (6.1-10.7) 11.7 (10.5-13.0)
Table 2. Description of follow-up data.
Late diagnosis of CLD
Model # (variables adjusted for) HR for late diagnosis versus 
non-late diagnosis (95% CI)
P-value
Model #1 (univariate - no adjustment) 1.47 (1.08-2.00) 0.013
Model #2 (socio demographic factors1) 1.35 (0.99-1.84) 0.056
Model #3 (as per model#2 + liver disease aetiology) 1.11 (0.79-1.55) 0.550
Model #4 (as per model #3 + disease stage2) 1.04 (0.74-1.48) 0.811
Table 3: Association between late diagnosis and survival following index CLD event, 
according to different levels of covariate adjustment
1 . Sociodemographic factors comprises: age, gender and birth outside UK; UK resident country; and Townsend deprivation index.
 2. disease stage comprises: platelet count at UKB interview, presence of bleeding varices at index advanced CLD event, chronic kidney disease 
at index advanced CLD event, ascites at index advanced CLD event, infection at index advanced CLD event. 
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